Miguel Angel Gentil

The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy (2009)

Ekberg, Henrik, Mamelok, Richard D, Oppenheimer, Federico, Sánchez-Plumed, Jaime, Gentil, Miguel Angel, ...

BACKGROUND: Exposure to mycophenolic acid (MPA), the primary active metabolite of mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies depending on the concomitantly...

The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy (2009)

Grinyó, Josep M., Ekberg, Henrik, Mamelok, Richard D., Oppenheimer, Federico, Sánchez-Plumed, Jaime, Gentil, Miguel Angel, ...

Background. Exposure to mycophenolic acid (MPA), the primary active metabolite of mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies depending on the concomitantly...

Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients (2008)

Aguilera, Isabel, Alvarez-Marquez, Antonia, Gentil, Miguel Angel, Fernandez-Alonso, Jorge, Fijo, Julia, Saez, Carmen, ...

Background. Chronic humoral rejection is a progressive form of graft injury, with defined diagnostic criteria, the crucial one being the evidence of circulating anti-donor antibodies. These...

Impact of the new drugs in the cost of maintenance immunosuppression of renal transplantation. Is it justified? (2004)

Gentil, Miguel Angel, Cantarell Aixendri, Carmen, González Roncero, Francisco M., Marco Franco, Julio E.

Background. The new immunosuppressive drugs control acute rejection better, and have potentially short-term economic advantages. However, their long-term cost-effectiveness must still be determined....